Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its financial results for the second quarter of 2025. The company reported a net loss of $2.2 million for this period, consistent with the net loss reported in the second quarter of 2024. Kiora's R&D expenses for Q2 2025 were $2.6 million, before accounting for $1.7 million in reimbursable expenses from Théa, reflecting an increase compared to the $2.0 million in R&D expenses for Q2 2024, which had $1.1 million in offsetting reimbursable expenses. This increase is mainly attributed to clinical trial activities. General and administrative expenses decreased slightly to $1.4 million from $1.5 million in the same quarter of the previous year. The company ended the quarter with $20.7 million in cash, cash equivalents, and short-term investments. Additionally, Kiora maintained a projected cash runway into late 2027, extending beyond anticipated data readouts for its KLARITY and ABACUS-2 trials, with potential for further extension through partnership milestones. In terms of operational updates, Kiora initiated KLARITY, a Phase 2 clinical trial for KIO-104 aimed at treating retinal inflammation, and extended market exclusivity of KIO-104 into 2043 with a new patent for ocular inflammatory disease treatments.